AstraZeneca Annual Report and 90 Form 20-F Information 2005 NOTES TO THE FINANCIAL STATEMENTS 1 OPERATING PROFIT 2005 2004 2003 $m $m $m Group operating profit 6,502 4,547 4,007 Charges included above for depreciation 965 921 990 for amortisation 272 306 296 for impairment 90 41 7 Gross profit 18,594 16,233 14,386 Impairment charges in 2005 relate to the write-down of assets associated with capacity reviews at manufacturing sites, primarily in the UK and France.
Cost of sales in 2004 includes charges against inventories and prepayments in respect of Exanta and Iressa totalling $195m.
In addition, the charge for impairment in 2004 arose from writing off property, plant and equipment and goodwill associated with Exanta and Iressa.
2005 2004 2003 $m $m $m Other operating income Royalties 165 95 90 Other income 28 131 98 193 226 188 Other income includes minor gains and losses arising from disposals under ongoing product and investment rationalisation programmes.
2 PROFIT ON SALE OF INTEREST IN JOINT VENTURE 2005 2004 2003 $m $m $m Profit on sale of interest in joint venture 219 Net taxation credit 9 Total profit on sale of interest in joint venture after taxation 228 The profit on sale of interest in joint venture relates to the disposal of the Groups interest in the Ordinary Share capital of Advanta BV.
There is a tax credit of $9m arising on costs associated with the disposal.
3 FINANCE INCOME AND EXPENSE 2005 2004 2003 $m $m $m Finance income Securities 15 10 21 Short term deposits 197 81 62 Expected return on post-employment defined benefit plan assets 448 390 277 Gain on disposal of interest rate swap 30 Dividend income 62 Net exchange gains 5 15 19 665 532 381 Finance expense Loan interest 42 29 6 Interest on short term borrowings and other financing costs 19 17 6 Discount on liability 3 Interest on post-employment defined benefit plan liabilities 433 398 284 Fair value losses on interest rate swaps 6 10 12 500 454 311 Net finance income 165 78 70 The amount of exchange gains recognised in profit or loss, other than those arising on financial instruments measured at fair value through profit or loss in accordance with IAS 39 see Note 15, is $5m 2004 $15m, 2003 $19m.
